MEDICARE PART D COST SHARING AND SPECIALTY DRUG INITIATION IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS

被引：0
|
作者：
Doshi, J. A. [1 ]
Li, P. [1 ]
Huo, H. [1 ]
Pettit, A. R. [1 ]
Kumar, R. [1 ]
Huntington, S. F. [2 ]
Weiss, B. M. [3 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Yale Univ, New Haven, CT USA
[3] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.035
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
ME2
引用
收藏
页码：A3 / A3
页数：1
相关论文
共 50 条
  • [21] Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007
    Mughal, Tariq
    Goldman, John M.
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 : S95 - S101
  • [22] Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries With Chronic Myeloid Leukemia Reply
    Winn, Aaron N.
    Keating, Nancy L.
    Dusetzina, Stacie B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (15) : 1745 - +
  • [23] Impact of Medicare Part D on Access to and Cost Sharing for Specialty Biologic Medications for Beneficiaries With Rheumatoid Arthritis
    Polinski, Jennifer M.
    Mohr, Penny E.
    Johnson, Lorraine
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (06): : 745 - 754
  • [24] Deficient cell cycle control in myeloid cells of patients with newly diagnosed chronic myeloid leukemia
    Schwab, R
    Peschel, C
    Despres, D
    Derigs, G
    Fischer, T
    Huber, C
    Aulitzky, WE
    CYTOKINES AND MOLECULAR THERAPY, 1995, 1 (04): : 281 - 288
  • [25] Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase
    Michihide Tokuhira
    Yuta Kimura
    Keiji Sugimoto
    Tomonori Nakazato
    Maho Ishikawa
    Isao Fujioka
    Tomoiku Takaku
    Noriyoshi Iriyama
    Eriko Sato
    Hiroyuki Fujita
    Yoshihiro Hatta
    Norio Komatsu
    Norio Asou
    Masahiro Kizaki
    Tatsuya Kawaguchi
    Medical Oncology, 2018, 35
  • [26] Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase
    Tokuhira, Michihide
    Kimura, Yuta
    Sugimoto, Keiji
    Nakazato, Tomonori
    Ishikawa, Maho
    Fujioka, Isao
    Takaku, Tomoiku
    Iriyama, Noriyoshi
    Sato, Eriko
    Fujita, Hiroyuki
    Hatta, Yoshihiro
    Komatsu, Norio
    Asou, Norio
    Kizaki, Masahiro
    Kawaguchi, Tatsuya
    MEDICAL ONCOLOGY, 2018, 35 (03)
  • [27] Imatinib mesylate in newly diagnosed patients of chronic myeloid leukemia chronic phase: A comparative study
    Jacob, L. A.
    Bapsy, P. P.
    Govindbabu, K.
    Lokanatha, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase
    Fallah, P.
    Amirizadeh, N.
    Poopak, B.
    Toogeh, G.
    Arefian, E.
    Kohram, F.
    Rad, S. M. A. Hosseini
    Kohram, M.
    Naghadeh, H. Teimori
    Soleimani, M.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2015, 37 (04) : 560 - 568
  • [29] Imatinib superior to interferon for newly diagnosed chronic myeloid leukemia
    不详
    FORMULARY, 2003, 38 (01) : 17 - +
  • [30] Leukapheresis in patients newly diagnosed with acute myeloid leukemia
    Villgran, Vipin
    Agha, Mounzer
    Raptis, Anastasios
    Hou, Jing-Zhou
    Farah, Rafic
    Lim, Seah H.
    Redner, Robert L.
    Im, Annie
    Sehgal, Alison
    Dorritie, Kathleen A.
    Kiss, Joseph E.
    Normolle, Daniel
    Boyiadzis, Michael
    TRANSFUSION AND APHERESIS SCIENCE, 2016, 55 (02) : 216 - 220
12345